Hodgkin Lymphoma: 20 Patient Questions About Diagnosis, Treatment, and Care in China

A diagnosis of Hodgkin lymphoma can introduce many unfamiliar terms in a few appointments. Understanding an abbreviation helps, but the more useful question is which decision it affects for you. These questions mainly concern adults; childhood disease, distinct pathology, and transplantation require their own considerations. A treatment proposal should connect the diagnosis and disease extent with your health, previous treatment, and the services actually available where care will take place.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

No. Infection, other lymphomas, and several other conditions can enlarge lymph nodes. Diagnosis usually requires sufficient tissue for a pathologist to assess its appearance and relevant tests. Bloodwork and imaging provide information but do not replace pathology. If an earlier sample was small, the report remains tentative, or the findings do not fit the clinical picture, review or further sampling may be appropriate. [S1][S66]
Autologous transplantation uses your own collected blood-forming stem cells, usually in conjunction with high-dose treatment. Allogeneic transplantation uses donor cells and brings additional issues, including donor selection and graft-versus-host disease. Their roles, preparation, and follow-up differ. Comparing only hospital-stay length or the shared word “transplant” misses the main clinical distinctions. [S14]
No. After end-of-treatment assessment confirms remission, the 2026 EHA guideline favors clinical follow-up and does not recommend routine surveillance PET/CT or CT without relevant symptoms. New symptoms, abnormal examination findings, or unresolved imaging questions can still justify targeted investigation. That is different from repeating a scan automatically when there is no clinical indication. [S2]

Quick answer

Full guide

1. Can an enlarged lymph node establish the diagnosis?

No. Infection, other lymphomas, and several other conditions can enlarge lymph nodes. Diagnosis usually requires sufficient tissue for a pathologist to assess its appearance and relevant tests. Bloodwork and imaging provide information but do not replace pathology. If an earlier sample was small, the report remains tentative, or the findings do not fit the clinical picture, review or further sampling may be appropriate. [S1][S66]

Bring the complete report and ask how slides or tissue blocks can be made available for review. Removing an enlarged node does not mean treatment for lymphoma is complete. Sampling establishes what the disease is; subsequent decisions depend on its type and overall distribution. When seeking another opinion, preserve the original material rather than relying only on a translated diagnostic sentence.

2. Is classical Hodgkin lymphoma the same as nodular lymphocyte-predominant disease?

They differ in pathology, clinical behavior, and treatment choices. Evidence about ABVD, brentuximab vedotin, and most checkpoint inhibitor strategies discussed here mainly concerns classical Hodgkin lymphoma. A nodular lymphocyte-predominant diagnosis requires discussion of its own characteristics and whether transformation or another finding changes management. The shared word “Hodgkin” is not enough to make the pathways interchangeable. [S1][S2]

If reports from different hospitals use different names, ask a hematopathology specialist to compare the original material. Choosing the label that sounds less serious is not a reliable solution. Clarifying the diagnosis helps prevent evidence from another lymphoma subtype or a drug indication for another population from being applied incorrectly to your case.

3. Does stage IV mean there is no possibility of cure?

No. Advanced Hodgkin lymphoma should not be equated automatically with advanced solid cancers. Treatment for some people with extensive disease still has curative intent. Stage describes distribution, while age, other illnesses, treatment tolerance, the regimen selected, and response also influence the outlook. A stage number alone cannot provide an individual prediction. [S1][S45]

At the same time, favorable overall results are not a guarantee for every person. Ask your clinician to explain the current goal, why the proposed treatment fits your situation, and what options would remain if the response were inadequate. Five-year survival statistics describe populations; they are neither a personal promise nor a rule that treatment effectiveness cannot be assessed until five years have passed.

4. What does a Deauville score on PET/CT tell me?

The score helps clinicians compare metabolic activity in a lesion with reference tissues. Its meaning depends on when the scan was performed, the treatment being used, and the response criteria in that pathway. A baseline scan, an interim scan, and an end-of-treatment scan do not answer exactly the same question. A number alone should not determine whether you stop treatment, switch drugs, or add radiotherapy. [S28][S2]

Infection and treatment-related inflammation can also affect appearances. If the result is uncertain, ask whether original-image review, another assessment, or tissue sampling would help. Increased uptake is not by itself proof of relapse. Making the complete images available is generally more useful for specialist comparison than sending a photograph of a single line in the report.

5. Does everyone receive ABVD as first-line treatment?

No. Early favorable, early unfavorable, and advanced disease create different choices, while age, heart and lung function, and other health problems also matter. ABVD remains an important regimen, but contemporary treatment includes other risk-adapted approaches and AVD combined with particular agents in defined settings. A newer name is not sufficient reason to choose a treatment. Ask whether the trial population, expected benefits, and risks resemble your circumstances. [S1][S2]

In March 2026, the FDA approved nivolumab with AVD in the United States for previously untreated stage III or IV classical Hodgkin lymphoma in adults and children aged 12 years and older. That is a US indication. Current Chinese authorization, use conditions, and hospital access require separate verification; an overseas announcement does not establish eligibility for treatment in China. [S3][S7]

6. Can I stop all chemotherapy when the interim PET is negative?

An interim negative scan does not authorize stopping treatment yourself. PET-adapted care changes particular components within a studied pathway. For example, a suitable approach may omit bleomycin after the specified assessment while the remaining chemotherapy continues. RATHL informs that specific discussion; it did not establish that all further treatment becomes unnecessary when an interim scan is negative. [S5]

Ask for a written explanation of what has been completed, which drugs remain, and the intended total course. Toxicity may require a separate adjustment, but the team must weigh disease control and recovery together. Missing an infusion independently and assuming it can simply be added later is not equivalent to a planned modification. Contact the service before changing an appointment when the change may affect treatment delivery.

7. Should surgery remove all affected lymph nodes?

Most Hodgkin lymphoma is not treated by surgically removing every involved site. Surgery commonly obtains diagnostic tissue, while other procedures may provide venous access or manage a particular complication. Local removal does not replace systemic therapy when disease affects multiple regions. A recommendation for another biopsy usually aims to clarify a result and guide the next decision, rather than remove every remaining mass. [S1][S8]

For a deep lesion, the sampling method should balance diagnostic value and procedural risk. Ask why that site has been chosen and which uncertainty the specimen should resolve. An operation without a clear purpose should not be accepted merely to achieve an image of complete removal; equally, having had a previous biopsy does not eliminate the need for a justified reassessment later.

8. Does a negative PET mean radiotherapy can always be omitted?

No. Findings from early-stage trials depend on the risk group, chemotherapy intensity, assessment timing, and PET interpretation rules. HD16 and HD17 studied different populations and treatment programs. A conclusion about omission in one setting cannot be extended to every person with early-stage disease. The discussion should consider disease control alongside exposure of organs such as the heart, lungs, or breast tissue. [S24][S25]

If radiotherapy is proposed, ask about the target, dose, and methods to protect normal tissues. If it is omitted, ask which evidence-based pathway supports that decision. Modern treatment volumes differ from historical large fields, so numerical risks from older approaches should not simply be assigned to someone receiving a current plan. Your actual treatment details are needed for later follow-up. [S16][S40]

9. Are brentuximab vedotin and PD-1 inhibitors the same type of drug?

No. Brentuximab vedotin is an antibody-drug conjugate directed at CD30, while PD-1 inhibitors work through a different immune mechanism. Their indications, combinations, and adverse effects differ. Doses cannot be converted between them, and one should not replace the other merely because a price or infusion schedule appears more convenient. Previous exposure, benefit, and toxicity influence later choices. [S1][S26]

Nerve symptoms deserve particular attention with a brentuximab-containing plan, while checkpoint inhibitor treatment requires recognition of immune-related organ inflammation. Keep generic drug names, administration dates, and reasons for changes. Brand names alone can cause confusion across countries. Whether a particular product is appropriate under current Chinese authorization must also be checked for the actual diagnosis and treatment setting. [S38][S37][S7]

10. What options remain if the disease returns?

First establish whether a finding represents relapse or refractory disease, with tissue reassessment when appropriate. The team should review earlier treatment, the duration of any remission, current organ function, and complications. Suitable patients may receive salvage therapy followed, after an appropriate response, by high-dose treatment and autologous transplantation. Other circumstances may lead to checkpoint inhibitors, antibody-drug conjugates, radiotherapy, or a clinical trial. [S1][S14]

There is no single pathway for everyone, and not every person is a transplant candidate. A high response rate in a small single-arm study does not establish the preferred treatment for all relapses. Ask whether the proposed step is intended to enable transplantation, provide ongoing disease control, relieve symptoms, or answer a research question. This makes comparisons between apparently similar options more meaningful. [S49][S50]

11. How do autologous and allogeneic transplantation differ?

Autologous transplantation uses your own collected blood-forming stem cells, usually in conjunction with high-dose treatment. Allogeneic transplantation uses donor cells and brings additional issues, including donor selection and graft-versus-host disease. Their roles, preparation, and follow-up differ. Comparing only hospital-stay length or the shared word “transplant” misses the main clinical distinctions. [S14]

Before either procedure, the team assesses disease status, organ function, infection, and available support. Follow-up after discharge may include frequent review, infection prevention, and a vaccination plan. International patients should identify a receiving transplant service at home before travel. Blood-count recovery does not mean all immune function has recovered, and discharge does not automatically establish fitness for a long international flight. [S57][S15]

12. Can CAR-T or NK-cell treatment simply be purchased as an established therapy?

Publication of a study does not establish that any commercially offered cell infusion has the same evidence. CD30 CAR-T and AFM13 combined with a particular NK-cell strategy have early clinical research in classical Hodgkin lymphoma or relevant CD30-positive populations. The exact product, manufacturing process, eligibility criteria, and regulatory status matter. Those studies do not establish Chinese marketing approval or prove that a particular center is recruiting. [S52][S53]

If considering research, request the study name, registration information, and informed-consent documentation, and let the study team assess eligibility. Clarify which expenses are covered, which are routine care, and how complications will be managed. A generic description such as “cell therapy” does not justify transferring results from a specific trial to an unverified infusion service. [S18][S59]

13. Can I take a fever medicine and wait until tomorrow?

Fever during chemotherapy or immune recovery can require urgent assessment, especially with low neutrophils. Follow the contact and emergency instructions supplied by your team and report the most recent treatment date. Taking medicine to conceal a temperature and waiting for the next scheduled appointment can delay infection management. Ask the assessing team about medication rather than using symptom improvement as proof that the danger has passed. [S9]

Marked breathlessness, chest pain, confusion, substantial bleeding, or inability to keep fluids down also require prompt local care. Carry a short medication and medical-history summary so emergency clinicians can identify chemotherapy, transplantation, or checkpoint inhibitor exposure. For an international patient, a reply from the original treating hospital is not a prerequisite for using nearby emergency services. [S56][S37]

14. Will a young person definitely lose fertility?

Not necessarily. Risk depends on drugs, cumulative exposure, age, radiation location, and treatments such as transplantation. If future parenthood matters, raise it before therapy starts so fertility preservation options can be discussed when the clinical situation allows. Being young, already having children, or receiving a familiar regimen does not remove the need to consider sperm, egg, or embryo preservation when appropriate. [S10][S11]

Return of menstruation and normal sexual function in men do not independently establish full reproductive capacity. Timing of pregnancy, the need for testing, and use of stored material require individualized discussion with the lymphoma and reproductive-health teams. Trial evidence about fertility after a particular regimen is useful but does not provide a personal guarantee. A universal internet waiting period should not replace a documented plan. [S27]

15. How long would I need to stay in China?

The answer depends on the regimen, assessment points, radiotherapy or transplantation, and changes required during treatment. The number of cycles, number of administrations, recovery intervals, and final assessment are different elements. An initial consultation can provide a conditional outline, which becomes more reliable after pathology review and clinical assessment. Another patient's length of stay is not a dependable promise for your case. [S20][S14]

Ask separately about diagnostic work, treatment visits, observation needs, end-of-treatment assessment, and conditions for returning home. If care will be divided between countries, confirm the ability to continue the intended drugs and transfer administration records, response assessments, and clinical responsibility. Travel bookings should allow changes when necessary. A fixed return ticket should not determine which clinical steps can safely be omitted.

16. What would treatment cost in Chinese yuan?

A reliable total cannot be supplied without a diagnosis, treatment pathway, and a written hospital estimate. Request separate figures for pathology and staging, drugs and administration, supportive care, radiotherapy, transplantation if relevant, and follow-up. Each line should identify its quantity, specification, and included services. Budget separately for accommodation, transport, interpretation, and possible extra time in the country. [S12][S60]

A drug's unit price is not the price of a complete course, and an international service may charge differently from ordinary outpatient care. Insurance, reimbursement, and study funding depend on individual eligibility. Ask for the estimate's date, assumptions, and exclusions. Payment instructions on a hospital website explain how bills are handled; they do not establish a patient-specific treatment quotation or a guaranteed spending cap. [S58][S59]

17. How can I judge whether a Chinese hospital fits my needs?

Start with the clinical problem it must address: specialist pathology, systemic lymphoma treatment, radiotherapy collaboration, or transplantation. Official Peking University Cancer Hospital pages describe lymphoma and transplant-related services, and Sun Yat-sen University Cancer Center pages describe medical oncology and its international center. These can provide contact routes, but they are not a ranking of suitability for an individual patient. [S30][S63][S61][S62]

A department's existence does not establish current stock of a specific drug, an available transplant bed, or a trial place. After sending records, confirm the receiving specialty, any required review, the proposed discussion, and the next steps. International coordination may help organize appointments, while the relevant clinical team remains responsible for medical decisions. Service descriptions should support contact, not substitute for case assessment.

18. Can I fly to China immediately while receiving treatment?

Fitness for travel needs individual assessment. Severe anemia, infection, bleeding risk, substantial breathlessness, or other instability may make a long flight unsuitable. Recent chemotherapy, transplantation, and immune suppression also affect planning. Cabin conditions, prolonged sitting, and the distance involved in transfers should be considered together with your health; there is no universal date or blood-count threshold appropriate for every patient. [S22][S64][S65]

If oxygen, wheelchair assistance, or medical accompaniment is required, check arrangements with the actual airline and ground transport providers. Acute illness while awaiting referral should be managed locally first. Travel-vaccine eligibility and fitness to fly are separate matters. A travel-medicine clinician needs the treatment and immune-status history, especially when considering vaccines that may be unsuitable during substantial immunosuppression. [S15]

19. Which medical records are most important to bring?

Prioritize complete pathology and review material, original imaging with reports, actual drug administration records, radiotherapy information, recent laboratory results, and major complication records. Make transplantation, serious immune toxicity, and severe allergies easy to find. Medicines should be identified by generic name, dose, and date, rather than only by a purchase receipt or a remembered brand. [S66][S13]

A one-page dated timeline can guide the reader while original documents and key translations remain available for verification. Do not crop patient identifiers, dates, or units from reports. Confirm release and receiving requirements for pathology material with both hospitals before transporting it. Knowing exactly what a reviewer needs can reduce avoidable delays or requests for another shipment after you arrive.

20. After remission, must I have PET scans every few months?

No. After end-of-treatment assessment confirms remission, the 2026 EHA guideline favors clinical follow-up and does not recommend routine surveillance PET/CT or CT without relevant symptoms. New symptoms, abnormal examination findings, or unresolved imaging questions can still justify targeted investigation. That is different from repeating a scan automatically when there is no clinical indication. [S2]

Before returning home, identify the receiving clinician and next assessment, and transfer a long-term plan based on actual treatment exposure. Cardiac, pulmonary, thyroid, reproductive, and other concerns should be considered where relevant. Transplant recovery or ongoing toxicity requires additional arrangements. Preserve the treatment summary for future doctors so that later care is based on the drugs, doses, radiation fields, and complications you actually experienced. [S67][S32][S57]